Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 8/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656954 | 0.95 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1MAOBMAPTALDH1A1 | |
| SCHEMBL10147497 | 0.91 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1MAPTCYP19A1 | |
| SCHEMBL10147476 | 0.88 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1MAPTCYP19A1 | |
| SCHEMBL10147656 | 0.86 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1MAOBMAPTCYP19A1 | |
| SCHEMBL10147487 | 0.86 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1MAPTALDH1A1GAA | |
| SCHEMBL10147590 | 0.86 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1MAPTALDH1A1GAA | |
| SCHEMBL10147496 | 0.85 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1MAPTALDH1A1GAA | |
| SCHEMBL656613 | 0.84 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1CYP19A1 | |
| SCHEMBL10147697 | 0.84 | MAOB (0.43) | MAOBMAPTALDH1A1GAARAB9A | |
| SCHEMBL7893313 | 0.82 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1MAPTGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885MAOB 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.